Loading...

Procaps Group, S.A.

PROCW•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.02
$0.005(33.79%)

Procaps Group, S.A. (PROCW) Stock Overview

Explore Procaps Group, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.9/100

Key Financials

Market Cap2M
P/E Ratio0.05
EPS (TTM)N/A
ROE-2.22%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.01

PROCW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Procaps Group, S.A. (PROCW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.05 and a market capitalization of 2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PROCWStats details for PROCW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PROCWAnalyst Recommendations details for PROCW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg.

CEO

Jose Antonio Toledo Vieira

Employees

5,500

Headquarters

9 rue de Bitbourg, Luxembourg City

Founded

2021

Frequently Asked Questions

;